X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs AUROBINDO PHARMA - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD AUROBINDO PHARMA MERCK LTD/
AUROBINDO PHARMA
 
P/E (TTM) x 48.8 14.8 330.4% View Chart
P/BV x 6.4 3.8 168.1% View Chart
Dividend Yield % 0.4 0.4 107.8%  

Financials

 MERCK LTD   AUROBINDO PHARMA
EQUITY SHARE DATA
    MERCK LTD
Dec-16
AUROBINDO PHARMA
Mar-17
MERCK LTD/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,060895 118.4%   
Low Rs623622 100.2%   
Sales per share (Unadj.) Rs632.4254.6 248.4%  
Earnings per share (Unadj.) Rs45.739.3 116.4%  
Cash flow per share (Unadj.) Rs62.346.6 133.8%  
Dividends per share (Unadj.) Rs11.002.50 440.0%  
Dividend yield (eoy) %1.30.3 396.6%  
Book value per share (Unadj.) Rs388.8160.0 243.1%  
Shares outstanding (eoy) m16.60585.88 2.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.33.0 44.7%   
Avg P/E ratio x18.419.3 95.3%  
P/CF ratio (eoy) x13.516.3 82.9%  
Price / Book Value ratio x2.24.7 45.6%  
Dividend payout %24.16.4 378.0%   
Avg Mkt Cap Rs m13,969444,390 3.1%   
No. of employees `0001.614.0 11.3%   
Total wages/salary Rs m1,48717,678 8.4%   
Avg. sales/employee Rs Th6,631.910,667.8 62.2%   
Avg. wages/employee Rs Th939.21,264.3 74.3%   
Avg. net profit/employee Rs Th479.41,645.8 29.1%   
INCOME DATA
Net Sales Rs m10,498149,157 7.0%  
Other income Rs m2421,159 20.9%   
Total revenues Rs m10,741150,316 7.1%   
Gross profit Rs m1,13534,343 3.3%  
Depreciation Rs m2764,276 6.4%   
Interest Rs m0667 0.0%   
Profit before tax Rs m1,10230,558 3.6%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3437,597 4.5%   
Profit after tax Rs m75923,012 3.3%  
Gross profit margin %10.823.0 47.0%  
Effective tax rate %31.124.9 125.3%   
Net profit margin %7.215.4 46.9%  
BALANCE SHEET DATA
Current assets Rs m6,41092,062 7.0%   
Current liabilities Rs m8,82866,223 13.3%   
Net working cap to sales %-23.017.3 -133.0%  
Current ratio x0.71.4 52.2%  
Inventory Days Days58106 54.4%  
Debtors Days Days3868 56.7%  
Net fixed assets Rs m1,40662,919 2.2%   
Share capital Rs m166586 28.3%   
"Free" reserves Rs m6,28693,133 6.7%   
Net worth Rs m6,45593,719 6.9%   
Long term debt Rs m01,814 0.0%   
Total assets Rs m8,828162,494 5.4%  
Interest coverage xNM46.8-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.9 129.5%   
Return on assets %8.614.6 59.0%  
Return on equity %11.824.6 47.9%  
Return on capital %17.132.7 52.2%  
Exports to sales %8.30-   
Imports to sales %21.00-   
Exports (fob) Rs m869NA-   
Imports (cif) Rs m2,209NA-   
Fx inflow Rs m95975,838 1.3%   
Fx outflow Rs m2,61230,224 8.6%   
Net fx Rs m-1,65345,613 -3.6%   
CASH FLOW
From Operations Rs m1,07032,786 3.3%  
From Investments Rs m-750-17,870 4.2%  
From Financial Activity Rs m-150-19,153 0.8%  
Net Cashflow Rs m171-4,239 -4.0%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 8.0 228.9%  
FIIs % 1.0 27.7 3.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 10.2 285.3%  
Shareholders   28,591 69,601 41.1%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare MERCK LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Jun 22, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE MERCK LTD WITH

MARKET STATS